ASTELLAS PHARMA

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 2005-01-01

Employees: -

Market Cap: $22.5B

Website: https://www.astellas.com/

Clinical Trials

A Study to Assess Effect of Exercise Program Provided by Smartphone Application on the Body Composition

Not Applicable

Completed

Conditions: Healthy Volunteers

Interventions: Behavioral: Exercise
Behavioral: No exercise

First Posted Date: 2019-12-11

Last Posted Date: 2024-11-05

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 100

Registration Number: NCT04194697

Locations: 🇯🇵
Site JP00001, Toshima-ku, Tokyo, Japan

A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)

Phase 1

Terminated

Conditions: Duchenne Muscular Dystrophy (DMD)

Interventions: Drug: Bocidelpar
Drug: Placebo

First Posted Date: 2019-12-04

Last Posted Date: 2024-10-22

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 8

Registration Number: NCT04184882

Locations: 🇺🇸
Kennedy Krieger Institute, Baltimore, Maryland, United States
🇺🇸
University of California Davis Health, Sacramento, California, United States
🇺🇸
UMass Memorial Medical Center, Worcester, Massachusetts, United States

and more 2 locations

Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies

Interventions: Drug: ASP1948

First Posted Date: 2019-09-19

Last Posted Date: 2024-11-01

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 9

Registration Number: NCT04094506

Locations: 🇯🇵
Site JP810001, Chuo-ku, Tokyo, Japan

Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis

Recruiting

Conditions: Rheumatoid Arthritis (RA)

Interventions: Drug: Peficitinib

First Posted Date: 2019-06-03

Last Posted Date: 2024-12-17

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 3000

Registration Number: NCT03971253

Locations: 🇯🇵
Site JP00005, Akita, Japan
🇯🇵
Site JP00038, Ehime, Japan
🇯🇵
Site JP00002, Aomori, Japan

and more 44 locations

Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: ASP8374

First Posted Date: 2019-05-10

Last Posted Date: 2024-11-13

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 6

Registration Number: NCT03945253

Locations: 🇯🇵
Site JP81001, Chuo-ku, Tokyo, Japan

Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury (AKI) Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery

Phase 2

Completed

Conditions: Acute Kidney Injury (AKI)

Interventions: Drug: ASP1128
Drug: Placebo

First Posted Date: 2019-05-08

Last Posted Date: 2024-12-04

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 351

Registration Number: NCT03941483

Locations: 🇺🇸
Moses H. Cone Memorial Hospital, Greensboro, North Carolina, United States
🇺🇸
Baptist Medical Center, Jackson, Mississippi, United States
🇺🇸
Lourdes Cardiology Services, Voorhees, New Jersey, United States

and more 24 locations

A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

Phase 4

Completed

Conditions: Metastatic Castration Resistant Prostate Cancer

Interventions: Drug: Enzalutamide
Drug: Androgen deprivation therapy (ADT)

First Posted Date: 2018-08-22

Last Posted Date: 2024-11-15

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 52

Registration Number: NCT03641560

Locations: 🇮🇳
Site IN00003, Nashik, India
🇮🇳
Site IN00002, Ahmedabad, India
🇮🇳
Site IN00008, Kolkata, India

and more 5 locations

Development of Visual Function Evaluation Method (2)

Completed

Conditions: Retinitis Pigmentosa

First Posted Date: 2018-08-10

Last Posted Date: 2024-10-21

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 8

Registration Number: NCT03626207

Locations: 🇯🇵
Site JP00001, Kobe, Hyogo, Japan

A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Not Applicable

Completed

Conditions: Gastric Cancer
Gastro-esophageal Junction (GEJ) Cancer

Interventions: Drug: Zolbetuximab

First Posted Date: 2018-05-18

Last Posted Date: 2024-12-02

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 18

Registration Number: NCT03528629

Locations: 🇯🇵
Site JP00001, Kashiwa, Chiba, Japan

Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)

Completed

Conditions: Irritable Bowel Syndrome With Constipation (IBS-C)
Chronic Constipation (CC) (Excluding Constipation Due to Organic Diseases)

Interventions: Drug: linaclotide

First Posted Date: 2018-03-21

Last Posted Date: 2024-10-18

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 2475

Registration Number: NCT03471728

Locations: 🇯🇵
Site JP00003, Iwate, Japan
🇯🇵
Site JP00039, Kochi, Japan
🇯🇵
Site JP00028, Hyogo, Japan

and more 44 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy